TMDX

TMDX

USD

TransMedics Group Inc. Common Stock

$121.176+0.866 (0.719%)

Real-time Price

Healthcare
Medical devices
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$120.310

High

$125.220

Low

$119.000

Volume

1.03M

Company Fundamentals

Market Cap

4.1B

Industry

Medical devices

Country

United States

Trading Stats

Avg Volume

1.00M

Exchange

NGM

Currency

USD

52-Week Range

Low $55Current $121.176High $145.5

Related News

PR Newswire

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

View more
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and raises the price target from $142 to $147.

View more
Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $147
Analyst Upgrades

Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140

Piper Sandler analyst Matt O'Brien maintains TransMedics Group with a Overweight and lowers the price target from $145 to $140.

View more
Piper Sandler Maintains Overweight on TransMedics Group, Lowers Price Target to $140
Analyst Upgrades

Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target

Needham analyst Mike Matson upgrades TransMedics Group from Hold to Buy and announces $148 price target.

View more
Needham Upgrades TransMedics Group to Buy, Announces $148 Price Target
Analyst Upgrades

Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target

Canaccord Genuity analyst William Plovanic maintains TransMedics Group with a Buy and maintains $142 price target.

View more
Canaccord Genuity Maintains Buy on TransMedics Group, Maintains $142 Price Target
Analyst Upgrades

Jefferies Initiates Coverage On TransMedics Group with Buy Rating, Announces Price Target of $145

Jefferies analyst Young Li initiates coverage on TransMedics Group with a Buy rating and announces Price Target of $145.